Roles of IFN-γ in tumor progression and regression: a review.
TLDR
The current knowledge concerning the roles of IFN-γ in the TME as a part of the complex immune response to cancer is discussed and the importance of identifying IFn-γ responsive patients to improve their sensitivity to immuno-therapies is highlighted.Abstract:
Interferon-γ (IFN-γ) plays a key role in activation of cellular immunity and subsequently, stimulation of antitumor immune-response. Based on its cytostatic, pro-apoptotic and antiproliferative functions, IFN-γ is considered potentially useful for adjuvant immunotherapy for different types of cancer. Moreover, it IFN-γ may inhibit angiogenesis in tumor tissue, induce regulatory T-cell apoptosis, and/or stimulate the activity of M1 proinflammatory macrophages to overcome tumor progression. However, the current understanding of the roles of IFN-γ in the tumor microenvironment (TME) may be misleading in terms of its clinical application. Some researchers believe it has anti-tumorigenic properties, while others suggest that it contributes to tumor growth and progression. In our recent work, we have shown that concentration of IFN-γ in the TME determines its function. Further, it was reported that tumors treated with low-dose IFN-γ acquired metastatic properties while those infused with high dose led to tumor regression. Pro-tumorigenic role may be described through IFN-γ signaling insensitivity, downregulation of major histocompatibility complexes, upregulation of indoleamine 2,3-dioxygenase, and checkpoint inhibitors such as programmed cell death ligand 1. Significant research efforts are required to decipher IFN-γ-dependent pro- and anti-tumorigenic effects. This review discusses the current knowledge concerning the roles of IFN-γ in the TME as a part of the complex immune response to cancer and highlights the importance of identifying IFN-γ responsive patients to improve their sensitivity to immuno-therapies.read more
Citations
More filters
Journal ArticleDOI
Combination strategies to maximize the benefits of cancer immunotherapy.
TL;DR: Wang et al. as mentioned in this paper discussed the relationship between cancer immune response and mechanisms of resistance to immunotherapy, and provided a comprehensive review on the latest clinical status of combination therapies (e.g., immunotherapy with chemotherapy, radiation therapy and targeted therapy).
Journal ArticleDOI
Differentiation and Regulation of TH Cells: A Balancing Act for Cancer Immunotherapy.
Amrita Basu,Ganesan Ramamoorthi,Gabriella Albert,Corey Gallen,Amber Beyer,Colin Snyder,Gary K. Koski,Mary L. Disis,Brian J. Czerniecki,Kodumudi Krithika N +9 more
TL;DR: An overview of the multifaceted positive and negative effects of TH cells, with an emphasis on regulation of different TH cell subtypes by various immune cells, and how a delicate balance of contradictory signals can influence overall success of cancer immunotherapy is presented.
Journal ArticleDOI
Immune Checkpoint Inhibitors in Cancer Therapy
Yavar Shiravand,Faezeh Khodadadi,Seyyed Mohammad Amin Kashani,Seyed Reza Hosseini-Fard,Shadi Hosseini,H. Sadeghirad,Rahul Ladwa,Kenneth J. O'Byrne,Arutha Kulasinghe +8 more
TL;DR: The current study aims to review the literature and updates on ICIs in cancer therapy, highlighting the role of biomarkers such as Tumour mutation burden, PDL-1 expression, microbiome, hypoxia, interferon-γ, and ECM in predicting responses to ICIs-based immunotherapy.
Journal ArticleDOI
Polysaccharide-based nanomedicines for cancer immunotherapy: A review.
Yujun Zeng,Yufan Xiang,Ruilong Sheng,Helena Tomás,João Rodrigues,Zhongwei Gu,Zhongwei Gu,Hu Zhang,Qiyong Gong,Qiyong Gong,Kui Luo,Kui Luo +11 more
TL;DR: A review of polysaccharide-based nanomedicines for cancer immunotherapy is presented in this paper, where the authors highlight recent advances in poly-saccharides-based nanoparticles.
Journal ArticleDOI
Chitosan-based nanodelivery systems for cancer therapy: Recent advances.
Asghar Narmani,Seid Mahdi Jafari +1 more
TL;DR: The properties, preparation, modification, and numerous pharmaceutical applications of chitosan-based drug nanodelivery systems in the diagnosis and therapy of cancer are presented in this paper.
References
More filters
Journal ArticleDOI
In situ click chemistry generation of cyclooxygenase-2 inhibitors
TL;DR: In situ click chemistry is used to develop COX-2 specific inhibitors with high in vivo anti-inflammatory activity, significantly higher than that of widely used selective cyclooxygenase-2 inhibitors.
Journal ArticleDOI
Interferon-γ: an overview of signals, mechanisms and functions
TL;DR: The current understanding of IFN‐γ ligand, receptor, ignal transduction, and cellular effects with a focus on macrophage responses and to a lesser extent, responses from other cell types that influence macrophages function during infection are reviewed.
Journal ArticleDOI
A novel transcription factor, T-bet, directs Th1 lineage commitment.
Susanne J. Szabo,Sean T Kim,Gina L. Costa,Xiankui Zhang,C. Garrison Fathman,Laurie H. Glimcher +5 more
TL;DR: T-bet initiates Th1 lineage development from naive Thp cells both by activating Th1 genetic programs and by repressing the opposing Th2 programs, as evidenced by the simultaneous induction of IFNgamma and repression of IL-4 and IL-5.
Journal ArticleDOI
Mechanisms of type-I- and type-II-interferon-mediated signalling.
TL;DR: It is anticipated that an increased understanding of the contributions of these recently identified pathways will advance current thinking about how interferons work.
Journal ArticleDOI
Macrophage plasticity, polarization, and function in health and disease.
Abbas Shapouri-Moghaddam,Saeed Mohammadian,Hossein Vazini,Mahdi Taghadosi,Seyed-Alireza Esmaeili,Fatemeh Mardani,Bita Seifi,Asadollah Mohammadi,Jalil Tavakol Afshari,Amirhossein Sahebkar +9 more
TL;DR: The protective and pathogenic role of the macrophage subsets in normal and pathological pregnancy, anti‐microbial defense, anti-tumor immunity, metabolic disease and obesity, asthma and allergy, atherosclerosis, fibrosis, wound healing, and autoimmunity are discussed.
Related Papers (5)
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.
Angel Garcia-Diaz,Daniel Sanghoon Shin,Blanca Homet Moreno,Justin Saco,Helena Escuin-Ordinas,Gabriel Abril Rodriguez,Jesse M. Zaretsky,Lu Sun,Willy Hugo,Xiaoyan Wang,Giulia Parisi,Cristina Puig Saus,Davis Y. Torrejon,Thomas G. Graeber,Begonya Comin-Anduix,Siwen Hu-Lieskovan,Robert Damoiseaux,Roger S. Lo,Antoni Ribas +18 more